Table 7.
IV iron EPO administered interaction: hazard ratios and patient survival
| Interaction | Patients (n) | IV Iron (mg/month) | EPO (103 u/week) | Hazard | HR 95% Confidence Limits | Median Survival (days) |
|---|---|---|---|---|---|---|
| A | 21 | 0 | 0–12.1 | 0.82 | 0.37, 1.83 | 317 |
| B | 89 | 1–202 | 0–12.1 | 0.45 | 0.28, 0.73 | 1623 |
| C | 238 | 202.1–455 | 0–12.1 | 0.86 | 0.60, 1.23 | 1104 |
| D | 83 | >455 | 0–12.1 | 1.37 | 0.81, 2.32 | 314 |
| E | 80 | 0 | 12.1–27.7 | 3.12 | 2.02, 4.81 | 152.5 |
| F | 124 | 1–202 | 12.1–27.7 | 0.35 | 0.23, 0.52 | 1672 |
| G | 458 | 202.1–455 | 12.1–27.7 | 0.68 | 0.51, 0.92 | 993 |
| H | 200 | > 455 | 12.1–27.7 | 1.6 | 1.11, 2.31 | 331.5 |
| I | 53 | 0 | > 27.7 | 1.27 | 0.72, 2.24 | 282 |
| J | 32 | 1–202 | > 27.7 | 0.41 | 0.24, 0.71 | 1247.5 |
| K | 187 | 202.1–455 | > 27.7 | 0.52 | 0.38, 0.72 | 985 |
| L | 158 | > 455 | > 27.7 | 620.5 |